STRATA SKIN SCIENCES INC (SSKN)

US86272A3059 - Common Stock

2.95  0 (0%)

Fundamental Rating

1

SSKN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. SSKN has a bad profitability rating. Also its financial health evaluation is rather negative. SSKN has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SSKN has reported negative net income.
In the past year SSKN had a positive cash flow from operations.
SSKN had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SSKN reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of SSKN (-23.34%) is comparable to the rest of the industry.
SSKN's Return On Equity of -100.43% is on the low side compared to the rest of the industry. SSKN is outperformed by 62.96% of its industry peers.
Industry RankSector Rank
ROA -23.34%
ROE -100.43%
ROIC N/A
ROA(3y)-14.07%
ROA(5y)-11.93%
ROE(3y)-40.48%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 55.47%, SSKN perfoms like the industry average, outperforming 48.68% of the companies in the same industry.
In the last couple of years the Gross Margin of SSKN has remained more or less at the same level.
SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-0.7%

More info and screens

1

2. Health

2.1 Basic Checks

SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SSKN has less shares outstanding
SSKN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, SSKN has a worse debt to assets ratio.

2.2 Solvency

SSKN has an Altman-Z score of -7.89. This is a bad value and indicates that SSKN is not financially healthy and even has some risk of bankruptcy.
SSKN has a worse Altman-Z score (-7.89) than 76.19% of its industry peers.
A Debt/Equity ratio of 1.62 is on the high side and indicates that SSKN has dependencies on debt financing.
SSKN has a Debt to Equity ratio of 1.62. This is amonst the worse of the industry: SSKN underperforms 82.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.62
Debt/FCF N/A
Altman-Z -7.89
ROIC/WACCN/A
WACC11.11%

2.3 Liquidity

A Current Ratio of 1.13 indicates that SSKN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.13, SSKN is doing worse than 88.89% of the companies in the same industry.
A Quick Ratio of 0.94 indicates that SSKN may have some problems paying its short term obligations.
The Quick ratio of SSKN (0.94) is worse than 80.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 0.94

More info and screens

3

3. Growth

3.1 Past

SSKN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -52.00%.
Looking at the last year, SSKN shows a decrease in Revenue. The Revenue has decreased by -7.36% in the last year.
Measured over the past years, SSKN shows a small growth in Revenue. The Revenue has been growing by 2.24% on average per year.
EPS 1Y (TTM)-52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.67%
Revenue 1Y (TTM)-7.36%
Revenue growth 3Y13.05%
Revenue growth 5Y2.24%
Sales Q2Q%-0.62%

3.2 Future

SSKN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.13% yearly.
The Revenue is expected to grow by 5.02% on average over the next years.
EPS Next Y61.68%
EPS Next 2Y27.38%
EPS Next 3Y24.13%
EPS Next 5YN/A
Revenue Next Year-4.81%
Revenue Next 2Y2.93%
Revenue Next 3Y5.02%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SSKN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SSKN's earnings are expected to grow with 24.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.38%
EPS Next 3Y24.13%

More info and screens

0

5. Dividend

5.1 Amount

SSKN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (1/14/2025, 8:06:55 PM)

2.95

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners26.1%
Inst Owner Change0%
Ins Owners2.56%
Ins Owner Change6.3%
Market Cap12.30M
Analysts82.5
Price Target16.32 (453.22%)
Short Float %0.17%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)38.85%
Min EPS beat(2)-18.09%
Max EPS beat(2)95.8%
EPS beat(4)1
Avg EPS beat(4)-103.38%
Min EPS beat(4)-439.22%
Max EPS beat(4)95.8%
EPS beat(8)3
Avg EPS beat(8)-39.49%
EPS beat(12)6
Avg EPS beat(12)-21.32%
EPS beat(16)9
Avg EPS beat(16)-2.37%
Revenue beat(2)2
Avg Revenue beat(2)6.22%
Min Revenue beat(2)1.03%
Max Revenue beat(2)11.4%
Revenue beat(4)2
Avg Revenue beat(4)-7.74%
Min Revenue beat(4)-39.19%
Max Revenue beat(4)11.4%
Revenue beat(8)3
Avg Revenue beat(8)-4.28%
Revenue beat(12)5
Avg Revenue beat(12)-1.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.82%
EPS NY rev (1m)0%
EPS NY rev (3m)46.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF 12.41
P/B 1.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.66
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)0.24
OCFY8.06%
SpS7.84
BVpS2.24
TBVpS-0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.34%
ROE -100.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.47%
FCFM N/A
ROA(3y)-14.07%
ROA(5y)-11.93%
ROE(3y)-40.48%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-0.7%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 1.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.5%
Cap/Sales 9.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 0.94
Altman-Z -7.89
F-Score3
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)85.03%
Cap/Depr(5y)75.45%
Cap/Sales(3y)12.35%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.67%
EPS Next Y61.68%
EPS Next 2Y27.38%
EPS Next 3Y24.13%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.36%
Revenue growth 3Y13.05%
Revenue growth 5Y2.24%
Sales Q2Q%-0.62%
Revenue Next Year-4.81%
Revenue Next 2Y2.93%
Revenue Next 3Y5.02%
Revenue Next 5YN/A
EBIT growth 1Y-22.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.65%
EBIT Next 3Y51.96%
EBIT Next 5YN/A
FCF growth 1Y44.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y330.47%
OCF growth 3YN/A
OCF growth 5YN/A